Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of dapagliflozin versus placebo on blood glucose in kidney transplant patients with diabetes
IRCT20251125068105N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and Kidney allograft status (RTx) comparing dapagliflozin with placebo (2 arms). Primary endpoint: Blood glucose reduction. Started Mar 2026; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Kidney allograft status (RTx)
Beyond the preview
Go deeper on IRCT20251125068105N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251125068105N1.